Bacterial production and direct functional screening of expanded molecular libraries for discovering inhibitors of protein aggregation
- PMID: 31663025
- PMCID: PMC6795521
- DOI: 10.1126/sciadv.aax5108
Bacterial production and direct functional screening of expanded molecular libraries for discovering inhibitors of protein aggregation
Abstract
Protein misfolding and aggregation are associated with a many human disorders, including Alzheimer's and Parkinson's diseases. Toward increasing the effectiveness of early-stage drug discovery for these conditions, we report a bacterial platform that enables the biosynthesis of molecular libraries with expanded diversities and their direct functional screening for discovering protein aggregation inhibitors. We illustrate this approach by performing, what is to our knowledge, the largest functional screen of small-size molecular entities described to date. We generated a combinatorial library of ~200 million drug-like, cyclic peptides and rapidly screened it for aggregation inhibitors against the amyloid-β peptide (Aβ42), linked to Alzheimer's disease. Through this procedure, we identified more than 400 macrocyclic compounds that efficiently reduce Aβ42 aggregation and toxicity in vitro and in vivo. Finally, we applied a combination of deep sequencing and mutagenesis analyses to demonstrate how this system can rapidly determine structure-activity relationships and define consensus motifs required for bioactivity.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).
Figures
References
-
- Chiti F., Dobson C. M., Protein misfolding, amyloid formation, and human disease: A summary of progress over the last decade. Annu. Rev. Biochem. 86, 27–68 (2017). - PubMed
-
- Coelho T., Merlini G., Bulawa C. E., Fleming J. A., Judge D. P., Kelly J. W., Maurer M. S., Plante-Bordeneuve V., Labaudiniere R., Mundayat R., Riley S., Lombardo I., Huertas P., Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis. Neurol. Ther. 5, 1–25 (2016). - PMC - PubMed
-
- Warnock D. G., Bichet D. G., Holida M., Goker-Alpan O., Nicholls K., Thomas M., Eyskens F., Shankar S., Adera M., Sitaraman S., Khanna R., Flanagan J. J., Wustman B. A., Barth J., Barlow C., Valenzano K. J., Lockhart D. J., Boudes P., Johnson F. K., Oral migalastat HCl leads to greater systemic exposure and tissue levels of active α-galactosidase A in Fabry patients when co-administered with infused agalsidase. PLOS ONE 10, e0134341 (2015). - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
